


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF “RIVASTIGMINE TRANSDERMAL PATCH”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the “Rivastigmine Transdermal Patch” (trade name: Debaitai (得百泰®)) developed by the Group has obtained approval for marketing from the National Medical Products Administration of China for the treatment of symptoms of mild to moderate Alzheimer’s disease. This is the first domestically produced rivastigmine transdermal patch approved for marketing.

Rivastigmine is a cholinesterase inhibitor used for the treatment of Alzheimer’s disease. Acetylcholine is an important neurotransmitter that transmits messages between neurons and plays a key role in brain regions associated with memory and learning. Rivastigmine reduces the breakdown of acetylcholine by inhibiting the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), which increases the level of acetylcholine in the central nervous system and improves the cognitive function in patients.

Rivastigmine transdermal patch enables a sustained and stable release of the drug over a longer period of time, maintaining stable blood drug concentration in patients and reducing side effects and fluctuations in efficacy caused by fluctuations in drug concentration. In addition, transdermal administration improves patient compliance, simplifies medication management, and provides a more comfortable treatment option for patients who are asleep, unresponsive or unable to swallow oral medicine.

Alzheimer's disease (AD) is a neurodegenerative condition with insidious onset and progressive impairment, and a major cause of senile dementia. With the gradual aggravation of the disease, the cognitive functions of patients deteriorate, affecting their daily lives and social interactions. Statistics showed that there were approximately 50 million dementia patients worldwide, 60-70% of whom suffered from Alzheimer's disease¹. In 2021, there were nearly 17 million existing cases of Alzheimer's disease and other forms of dementia in China². With the rapid aging of the global population, the incidence rate of Alzheimer's disease is rising year by year, which may impose a heavy burden on the society's healthcare and elderly resources.

With rich experience in the research and development and production of patches, the Group is a leading research and development and industrialization base for modern topical transdermal patches in China. Rivastigmine transdermal patch is another key product incubated by the patch platform of the Group. Adhering to the mission of "improving the quality of life and safeguarding human dignity", the Group is committed to helping to alleviate the burden of patients and their families and bringing warmth to more people with health technologies.

Sources:

1. World Alzheimer Report 2022 – Life after diagnosis: navigating treatment, care and support
2. WANG Gang, QI Jin Lei, LIU Xin Ya, et al. China Alzheimer's Disease Report (中國阿爾茨海默病報告) 2024[J]. Theory and Practice of Diagnostics (診斷學理論與實踐), 2024, 23(03): 219-256.doi: 10.16150/j.1671-2870.2024.03.001

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 25 September 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.